Clinical trials: Mammary Tumor
Breast Cancer
Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating women with previously treated…
- Trial name
- NCT00706615
- Testing
- Ad-sig-hMUC-1/ecdCD40L vaccine
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer
Combination Chemotherapy for Metastatic Breast Cancer
The purpose of this study is to determine the objective tumor response of the first-line therapy combination of gemcitabine and cisplatin in patients with metastatic breast cancer
- Trial name
- NCT00191815
- Testing
- Gemcitabine, cisplatin
- Where
- 2 sites in Germany, Russia
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
This phase I trial tests the safety, side effects, and best dose of a personalized vaccine (tumor membrane vesicle or TMV vaccine) by itself and in combination with checkpoint inhibitor (pembrolizumab or ipilimumab) in treating…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT06324240
- Testing
- Ipilimumab, Pembrolizumab, Vaccine Therapy
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Emory University
Breast Cancer
Real-world Study on Shenbailing Granules for Improving Qi and Blood Deficiency in Patients After Breast Cancer Surgery
This study aims to explore the clinical efficacy of Shenbailing granules in improving quality of life and reducing cancer-related fatigue in a real-world setting, with the goal of providing clinical evidence for the use of…
- Trial name
- NCT06881550
- Testing
- Shenbailing
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Caigang Liu
Breast Cancer
Role of FGF21 in Breast Cancer
The present study aims to evaluate the serum level of FGF-21 in patients with breast cancer and its correlation with clinical, laboratory, and pathological data.
- Trial name
- NCT07113418
- Testing
- ELISA
- Where
- Egypt
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Assiut University
Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable)…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT02498613
- Testing
- 18F-Fluoromisonidazole, Cediranib Maleate, Laboratory Biomarker Analysis
- Where
- 16 sites in United States, Canada
- Volunteers
- 122 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Study of E7389 for Advanced or Metastatic Breast Cancer
The purpose of this study (E7389-J081-224; hereafter referred to as Study 224) is to evaluate the safety of patients who continue to receive E7389 after completing the Phase II clinical study (E7389-J081-221; hereafter referred…
- Trial name
- NCT00965523
- Testing
- Eribulin Mesylate
- Where
- 5 sites in Japan
- Volunteers
- 81 people
- Sponsor
- Eisai Co., Ltd.
Cancer, Breast Cancer
An EORTC Study Updating the QLQ-BR23 to BR45
Female breast cancer is still the most frequent type of cancer in Europe with 21 per 100,000 women .The EORTC QLQ-BR23 was one of the first modules developed to be used in conjunction with the core questionnaire EORTC QLQ-C30 and…
- Trial name
- NCT04270123
- Testing
- EORTC QLQ-BR45 questionnaire
- Where
- United Kingdom
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Leeds
Advanced Solid Tumours, Breast Cancer
The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors
This is a phase 1, First-In-Human, open label study, trialing a new PARP (poly-ADP ribose polymerase) inhibitor medication IMP4297 in participants with advanced solid tumour.
- Conditions
- Advanced Solid Tumours, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT03507543
- Testing
- IMP4297
- Where
- 3 sites in Australia
- Volunteers
- 39 people
- Sponsor
- Impact Therapeutics, Inc.
Breast Cancer
Efficacy Verification in Early Diagnosis and Management of Lymphedema Through Home Body Water Analyzer
Breast cancer is the second most common cancer in women. One in five women who have been treated for breast cancer develop lymphedema. Lymphedema is a very common result of breast cancer and its treatment.
- Trial name
- NCT06580743
- Testing
- No intervention
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Minnesota
Breast Cancer Lymphedema, Secondary Lymphedema
Lymphaticovenous Anastomosis as Treatment for Lymphedema
The primary aim of this study is to investigate and test whether the use of combined indocyanine green (ICG) lymphography and ultra high frequency ultrasonography can correctly identify lymphatic vessels and venoles in close…
- Conditions
- Breast Cancer Lymphedema, Secondary Lymphedema, Iatrogenic Lymphedema, Lymphedema
- Trial name
- NCT05441943
- Testing
- Lymphovenous anastomosis
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Odense University Hospital
Fear, Anxiety
The Effect of 360° Virtual Reality Movies on Fear and Anxiety
To assess the effect of web-based 360° Virtual Reality movies on fear and anxiety, The investigators would like to assess the patient-perceived level of fear and anxiety quantitatively, making use of several questionnaires.
- Conditions
- Fear, Anxiety, Breast Cancer, Lung Cancer
- Trial name
- ENGAGE (NCT06199050)
- Testing
- Questionnaire: SPIRIT, Questionnaire: HADS, Questionnaire: QSC-R23
- Where
- Netherlands
- Volunteers
- 292 people
- Sponsor
- Maastricht Radiation Oncology
Breast Cancer
Biological Matrices Versus Synthetic Meshes
In this feasibility study, 60 women undergoing reconstruction will be randomly allocated to receive biological or synthetic mesh and followed for 6 months.
- Trial name
- BIOSYM (NCT05449691)
- Testing
- One-stage immediate breast reconstruction
- Where
- 5 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- University Hospitals of Derby and Burton NHS Foundation Trust
Radiotherapy Side Effect, Locoregional Recurrence
RCT Comparing 2 Radiotherapy HypoFractionation Schedules In Breast Cancer Patients
This is a prospective randomized Phase III trial to assess efficiency of two post mastectomy hypofractionation schedules (40 Gy /15 fx / 3 weeks, 5 days per week VS 28.5 Gy delivered in 5 once-weekly fractions of 5.7 Gy each…
- Trial name
- Breastcancer (NCT04550910)
- Testing
- Hypofractionation Schedules for Breast Cancer patients after mastecomy
- Where
- Egypt
- Volunteers
- 166 people
- Sponsor
- National Cancer Institute, Egypt
Breast Cancer Metastatic, Treatment Efficacy
A ReaL World Study of DS-8201
A ReaL world study of DS-8201
- Trial name
- EXPLORE (NCT06945224)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Breast Cancer
A Master Protocol Empowering Mechanobiology Translation Research in Breast Cancer
METAMECH is a master observational protocol designed to empower a bi-directional collaboration between basic and clinical research, an essential prerequisite to feed and implement precision oncology.
- Trial name
- METAMECH (NCT04625023)
- Testing
- Observational
- Where
- 10 sites in Italy
- Volunteers
- 1,500 people
- Sponsor
- IFOM ETS - The AIRC Institute of Molecular Oncology
Breast Cancer, Metastasis, Neoplasm
Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC)
The primary objective of this study is to evaluate the efficacy and tolerability of sequential use of vinorelbine and capecitabine as first line therapy in patients with MBC.
- Trial name
- NCT00629148
- Testing
- Vinorelbine and Capecitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Sarcopenia, Paclitaxel Induced Neuropathy
Sarcopenia and Paclitaxel-Induced Neuropathy in Early Stage Breast Cancer (Neuro-Sarc)
This prospective observational study aims to investigate the relationship between sarcopenia and the development of paclitaxel-induced peripheral neuropathy in patients with early-stage breast cancer.
- Conditions
- Sarcopenia, Paclitaxel Induced Neuropathy, Breast Carcinoma
- Trial name
- Neuro-Sarc (NCT06996548)
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Gazi University
Breast Cancer, Adherence, Medication
Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer
Breast cancer is the most common malignancy in women, with HR+/HER2- early breast cancer accounting for approximately 70% of cases.
- Trial name
- riboADHERE (NCT07630948)
- Testing
- Adherence package consisting of additional education and adherence reminders
- Where
- Slovenia
- Volunteers
- 90 people
- Sponsor
- Institute of Oncology Ljubljana
Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
Patients with advanced HER2+ breast cancer on maintenance trastuzumab/pertuzumab or T-DM1 with 1st or 2nd intracranial disease event (brain metastases) and stable extracranial disease will be enrolled.
- Conditions
- Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
- Trial name
- BRIDGET (NCT05323955)
- Testing
- Trastuzumab, Trastuzumab Emtansine (T-DM1), Pertuzumab
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carey Anders, M.D.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.